Pharmacokinetics of Zidovudine Dosed Twice Daily According to World Health Organization Weight Bands in Ugandan HIV-infected Children

نویسندگان

  • Quirine Fillekes
  • Lindsay Kendall
  • Sabrina Kitaka
  • Peter Mugyenyi
  • Philippa Musoke
  • Milly Ndigendawani
  • Mutsa Bwakura-Dangarembizi
  • Diana M. Gibb
  • David Burger
  • Ann Sarah Walker
چکیده

Data on zidovudine pharmacokinetics in children dosed using World Health Organization weight bands are limited. About 45 HIV-infected, Ugandan children, 3.4 (2.6-6.2) years, had intensive pharmacokinetic sampling. Geometric mean zidovudine AUC0-12h was 3.0 h.mg/L, which is higher than previously observed in adults, and was independently higher in those receiving higher doses, younger and underweight children. Higher exposure was also marginally associated with lower hemoglobin.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.

BACKGROUND No data on once-daily dosing of nucleoside analogues in African children currently exist. We compared the pharmacokinetics (PK) of once- versus twice-daily lamivudine and abacavir treatment using the World Health Organization recommended weight band dosing of scored adult tablets. METHODS HIV type-1 (HIV-1)-infected Ugandan children aged 3-12 years receiving antiretroviral therapy ...

متن کامل

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children

Methods Eligible children from 2 Ugandan centres in the ARROW trial, weighing 12-15kg, had taken ZDV, 3TC and ABC syrups twice daily for at least 24 weeks, and were ready to switch from syrups to scored tablets. Children were expected to remain in the 12-15kg weight band (i.e. same dosing band) for the next 4 weeks. Those with illnesses affecting PK (e.g., severe diarrhea, vomiting) were inelig...

متن کامل

Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.

BACKGROUND The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL). METHODS This was a prospective randomized three-way crossover study. Patients (8-<12 kg, 18...

متن کامل

Insulin Resistance and Markers of Inflammation in HIV-infected Ugandan Children in the CHAPAS-3 Trial.

BACKGROUND Few studies have investigated metabolic complications in HIV-infected African children and their relation with inflammation. METHODS We compared baseline and changes in insulin resistance [homeostatic model assessment of insulin resistance (HOMA-IR)] and in markers of inflammation over 48 weeks, in a subset of antiretroviral therapy (ART)-naive Ugandan children from the Children wi...

متن کامل

Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics

Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA, in October 2007, for the treatment of HIV-1 infection in combination with other antiretroviral agents. Raltegravir can be used in treatment-naïve and -experienced patients, as well as for the treatment of multidrug-resistant infection. Raltegravir exists in two formulations: a film-coated tablet admi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 33  شماره 

صفحات  -

تاریخ انتشار 2014